Pembrolizumab-Induced Skin Reactions
The rashes caused by pembrolizumab (Keytruda) are most commonly called "maculopapular rash," "pruritus" (itching), and "vitiligo" (in melanoma patients), though various other specific dermatologic reactions including lichenoid eruptions, eczematous dermatitis, psoriasiform reactions, and rarely life-threatening conditions like Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and bullous pemphigoid have been reported. 1, 2
Common Dermatologic Adverse Events
According to ESMO guidelines, skin adverse events occur in approximately 34% of patients treated with pembrolizumab 1. The most frequent presentations include:
Primary Skin Reactions:
- Maculopapular rash (15% of patients on anti-PD-1 monotherapy)
- Pruritus (13-20% of patients)
- Vitiligo (predominantly in melanoma patients, up to 25% in some studies)
These typically develop within the first few weeks after treatment initiation, though delayed onset after several months is possible 2.
Less Common but Important Reactions:
- Lichenoid eruptions 2, 3, 4
- Eczematous dermatitis
- Psoriasiform reactions (including exacerbation of pre-existing psoriasis) 1
- Bullous dermatitis 5
- Alopecia areata
- Xerosis cutis (dry skin)
- Photosensitivity
Severity Grading
The CTCAE classification grades these rashes as 1:
- Grade 1: Macules/papules covering <10% body surface area (BSA)
- Grade 2: 10-30% BSA coverage
- Grade 3: >30% BSA coverage, limiting self-care activities
- Grade 4: Life-threatening conditions (SJS/TEN, DRESS syndrome, bullous dermatitis >30% BSA requiring ICU)
Critical Pitfall to Avoid
Serious skin reactions are rare (<3% Grade 3-4 with monotherapy) but potentially fatal 1. You must immediately rule out dermatologic emergencies including:
- DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms)
- Stevens-Johnson Syndrome/TEN
- Acute febrile neutrophilic dermatosis (Sweet syndrome)
- Bullous pemphigoid 5
These require permanent discontinuation of pembrolizumab, immediate hospitalization, and specialist dermatology consultation 1.
Clinical Significance
Vitiligo development in melanoma patients is associated with favorable treatment response 1, making it a potentially positive prognostic indicator rather than purely an adverse event.
The FDA label confirms these dermatologic reactions, listing rash, itching, and various skin manifestations as common side effects, with specific mention that children may experience different frequencies than adults 6.